Leap therapeutics says cash, cash equivalents and marketable securities totaled $10.1 mln at sept. 30, 2019

Leap therapeutics reports third quarter 2019 financial results.leap therapeutics inc - cash, cash equivalents and marketable securities totaled $10.1 million at september 30, 2019.leap therapeutics inc - de-prioritizing further development in trx518 to focus resources on advancing dkn-01.
LPTX Ratings Summary
LPTX Quant Ranking